Similar articles

• Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B.

  Brunetto MR, Moriconi F, Bonino F, Lau GK, Farci P, Yurdaydin C, Piratvisuth T, Luo K, Wang Y, Hadziyannis S, Wolf E, McCloud P, Batrla R, Marcellin P. Brunetto MR, et al. Hepatology. 2009 Apr;49(4):1141-50. doi: 10.1002/hep.22760. Hepatology. 2009. PMID: 19338056
• Quantitative hepatitis B surface antigen combined with hepatitis B e antigen as sustained virological response predictors during extended therapy with Peginterferon alfa-2a for hepatitis B e antigen-positive chronic hepatitis B.

  Chen J, Zhang DH, Xu CR, Zhu MY, Yang ZT, Gong QM, Yu DM, Zhang XX. Chen J, et al. J Clin Virol. 2015 Nov;72:88-94. doi: 10.1016/j.jcv.2015.09.012. Epub 2015 Oct 9. J Clin Virol. 2015. PMID: 26476325
• Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels.

  Rijckborst V, Hansen BE, Cakaloglu Y, Ferenci P, Tabak F, Akdogan M, Simon K, Akarca US, Flisiak R, Verhey E, Van Vuuren AJ, Boucher CA, ter Borg MJ, Janssen HL. Rijckborst V, et al. Hepatology. 2010 Aug;52(2):454-61. doi: 10.1002/hep.23722. Hepatology. 2010. PMID: 20683945 Clinical Trial.
• Benefits and risks of interferon therapy for hepatitis B.

  Perrillo R. Perrillo R. Hepatology. 2009 May;49(5 Suppl):S103-11. doi: 10.1002/hep.22956. Hepatology. 2009. PMID: 19399806
• Hepatitis B surface antigen quantification: why and how to use it in 2011 - a core group report.

  Chan HL, Thompson A, Martinot-Peignoux M, Piratvisuth T, Cornberg M, Brunetto MR, Tillmann HL, Kao JH, Jia JD, Wedemeyer H, Locarnini S, Janssen HL, Marcellin P. Chan HL, et al. J Hepatol. 2011 Nov;55(5):1121-31. doi: 10.1016/j.jhep.2011.06.006. Epub 2011 Jun 28. J Hepatol. 2011. PMID: 21718667 Review.